Inventor · disambiguated record
Ko-Chung Lin
Also filed as: LIN KO C · LIN KO-CHUNG
38 granted patents·15 pending applications·429 citations·filing 1992–2025
98Inventor score
Top patents by PatentIndex Score
53 records- 0195US5482947ARetroviral protease inhibitorsFiled 1993·Granted Jan 9, 1996·38 cites·18 claims
- 0290US5610190ARetroviral protease inhibitorsSEARLE & CO·Filed 1995·Granted Mar 11, 1997·27 cites·48 claims
- 0388US6649600B1Adenosine receptor antagonists and methods of making and using the sameBIOGEN INC·Filed 2000·Granted Nov 18, 2003·31 cites·38 claims
- 0484US5703076ARetroviral protease inhibitorsSEARLE & CO·Filed 1995·Granted Dec 30, 1997·23 cites·35 claims
- 0582US6506759B1Retroviral protease inhibitorsMONSANTO CO·Filed 2000·Granted Jan 14, 2003·6 cites·40 claims
- 0680US6762187B2Retroviral protease inhibitorsMONSANTO CO·Filed 2002·Granted Jul 13, 2004·5 cites·20 claims
- 0780US6306840B1Cell adhesion inhibitorsBIOGEN INC·Filed 1995·Granted Oct 23, 2001·38 cites·38 claims
- 0879US7022686B2A1 adenosine receptro antagonistsBIOGEN IDEC INC·Filed 2003·Granted Apr 4, 2006·10 cites·22 claims
- 0979US6630512B2Cell adhesion inhibitorsBIOGEN INC·Filed 2001·Granted Oct 7, 2003·9 cites·53 claims
- 1079US6624152B2Cell adhesion inhibitorsBIOGEN INC·Filed 2001·Granted Sep 23, 2003·9 cites·34 claims
- 1179US6596687B1Cell adhesion inhibitorsBIOGEN INC·Filed 2000·Granted Jul 22, 2003·12 cites·46 claims
- 1278US7001921B1Cell adhesion inhibitorsBIOGEN IDEC INC·Filed 2003·Granted Feb 21, 2006·7 cites·9 claims
- 1378US5648364ARetroviral protease inhibitorsMONSANTO CO·Filed 1995·Granted Jul 15, 1997·12 cites·26 claims
- 1477US5756534ARetroviral protease inhibitorsMONSANTO CO·Filed 1995·Granted May 26, 1998·11 cites·30 claims
- 1577US5475013ARetroviral protease inhibitorsMONSANTO CO·Filed 1992·Granted Dec 12, 1995·31 cites·57 claims
- 1676US5622949ARetroviral protease inhibitorsSEARLE & CO·Filed 1995·Granted Apr 22, 1997·12 cites·58 claims
- 1775US12343381B2Dosage regimen for pegylated interferonPHARMAESSENTIA CORP·Filed 2022·Granted Jul 1, 2025·0 cites·22 claims
- 1875US5643924ARetroviral protease inhibitorsMONSANTO COMPANY OF ST LOUIS·Filed 1995·Granted Jul 1, 1997·11 cites·66 claims
- 1975US5510349ARetroviral protease inhibitorsSEARLE & CO·Filed 1995·Granted Apr 23, 1996·28 cites·46 claims
- 2074US6605601B2A1 adenosine receptor antagonistsBIOGEN INC·Filed 2001·Granted Aug 12, 2003·6 cites·19 claims
- 2174US6376538B1Cell adhesion inhibitorsBIOGEN INC·Filed 1996·Granted Apr 23, 2002·26 cites·56 claims
- 2272US8273343B2Protein-polymer conjugatesLIN KO-CHUNG·Filed 2009·Granted Sep 25, 2012·1 cites·18 claims
- 2372US6180646B1Retroviral protease inhibitorsMONSANTO CO·Filed 1998·Granted Jan 30, 2001·8 cites·31 claims
- 2472US5948790ARetroviral protease inhibitorsMONSANTO CO·Filed 1997·Granted Sep 7, 1999·8 cites·21 claims
- 2571US6875743B1Cell adhesion inhibitorsBIOGEN INC·Filed 2000·Granted Apr 5, 2005·3 cites·38 claims
- 2668US2008103311A1Retroviral protease inhibitorsPHARMACIA CORP·Filed 2007·Application pending·0 cites
- 2767US5475027ARetroviral protease inhibitorsSEARLE & CO·Filed 1993·Granted Dec 12, 1995·21 cites·16 claims
- 2866US7312333B2Retroviral protease inhibitorsPHARMACIA CORP·Filed 2006·Granted Dec 25, 2007·0 cites·8 claims
- 2966US7026485B2Retroviral protease inhibitorsSEARLE & CO·Filed 2004·Granted Apr 11, 2006·1 cites·6 claims
- 3066US2023096991A1Method of using pegylated interferon-alphaPHARMAESSENTIA CORP·Filed 2022·Application pending·0 cites
- 3166US2025186552A1Dosage regimen for pegylated interferonPHARMAESSENTIA CORP·Filed 2025·Application pending·0 cites
- 3265US2025101484A1Method to increase drug substance yieldPHARMAESSENTIA CORP·Filed 2024·Application pending·0 cites
- 3364US8617532B2Therapeutic use of interferon-polymer conjugatesLIN KO-CHUNG·Filed 2010·Granted Dec 31, 2013·1 cites·10 claims
- 3462US2025195616A1Method of using pegylated interferon-alphaPHARMAESSENTIA CORP·Filed 2025·Application pending·0 cites
- 3561US2024139142A1Method for preventing or treating liver diseaseTAIPEI VETERANS GENERAL HOSPITAL·Filed 2023·Application pending·0 cites
- 3660US6248713B1Cell adhesion inhibitorsBIOGEN INC·Filed 1995·Granted Jun 19, 2001·16 cites·13 claims
- 3760US2023057788A1Method of treating chronic myeloid leukemia using pegylated interferon and tyrosine kinase inhibitorPHARMAESSENTIA CORP·Filed 2022·Application pending·0 cites
- 3859US6239108B1Cell adhesion inhibitorsBIOGEN INC·Filed 1996·Granted May 29, 2001·12 cites·49 claims
- 3957US11559567B2Dosage regimen for pegylated interferonPHARMAESSENTIA CORP·Filed 2015·Granted Jan 24, 2023·0 cites·20 claims
- 4057US2022152156A1Method of using pegylated interferon-alphaPHARMAESSENTIA CORP·Filed 2021·Application pending·0 cites
- 4156US2006166866A1Cell adhesion inhibitorsBIOGEN INC A MASSACHUSETTS COR·Filed 2003·Application pending·0 cites
- 4255US2004067966A1Adenosine receptor antagonists and methods of making and using the sameBIOGEN INC·Filed 2003·Application pending·0 cites
- 4355US2022362343A1Method of reducing tet2 mutant allele burdenPHARMAESSENTIA CORP·Filed 2022·Application pending·0 cites
- 4452US7579354B2Adenosine receptor antagonists and methods of making and using the sameKIESMAN WILLIAM F·Filed 2006·Granted Aug 25, 2009·0 cites·39 claims
- 4552US5620977ARetroviral protease inhibitorsSEARLE & CO·Filed 1995·Granted Apr 15, 1997·3 cites·59 claims
- 4652US2007015732A1Adenosine receptor antagonists and methods of making and using the sameKIESMAN WILLIAM F·Filed 2006·Application pending·0 cites
- 4751US8143214B2Protein-polymer conjugatesLIN KO-CHUNG·Filed 2008·Granted Mar 27, 2012·0 cites·12 claims
- 4851US5698569ARetroviral protease inhibitorsSEARLE & CO·Filed 1995·Granted Dec 16, 1997·3 cites·49 claims
- 4948US2025269045A1Unique pegylated granulocyte colony stimulating factor, methods of use and preparation thereofPHARMAESSENTIA CORP·Filed 2025·Application pending·0 cites
- 5044US2011098451A1Peptide-polymer conjugatesPHARMAESSENTIA CORP·Filed 2010·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →